摘要:

AbstractThe ability of a [111In]bleomycin complex ([111In]BLMC) to kill five cell lines of human lung cancer (small cell lung cancer) was investigated. Cells were exposed to either 0.9% NaC1, [111In]C13, BLM, [111In]BLMC, nonradioactive InC13, or In-BLMC for 60 minutes, plated in soft agarose, and assessed for colony formation. [111In]BLMC (40–200μ;C) carried by 15–25μ;g BLM/ml) was more cytotoxic than BLM (15–25μ;g BLM/ml) by a factor of 1.6–5.3 for five cell lines. The percent survival of N417 cells was 28.4 for [111In]BLMC (40μ;Ci/15μ;g BLM/ml) and 54.3 for BLM (15μ;g/ml); 1.9 for [111In]BLMC (200μ;Ci/25μ;g BLM/ml), and 10.0 for BLM (25μ;g/ml).111InC13(200μ;Ci/ml) and nonradioactive InC13failed to inhibit colony formation. The new [111In]BLMC may be useful for therapy of some lung cancer patients.

ISSN:0735-7907    

DOI:10.3109/07357908909017528

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractCirculating osteocalcin (BGP), the major noncollagenous bone protein, is elevated in patients with certain metabolic bone disease while its behavior in cancer patients, particularly those with bone metastases, is unclear. We measured circulating BGP in 37 healthy females, in 13 female patients with benign breast disease, and in a group of 51 cancer patients (breast, lung, prostate, and bladder) with and without bone metastases, before and after 4′-epidoxorubicin (4′-Epidx) therapy (4′-Epidx 120 mg/m2every 3 weeks). Under basal conditions, mean BGP levels of all of these subjects fell within the normal range of 2.0–5.0 ng/ml (mean SD, 4.8 1.0 ng/ml). In cancer patients without bone metastases BGP levels measured before and after 4′-Epidx therapy were not significantly different (4.4 versus 4.6 ng/ml). Only in breast cancer patients with multiple bone metastases was circulating BGP higher after the onset of antiblastic treatment and through the entire course of therapy, accompanied by bone pain remission and regression of bone lesions (BGP = 6.7 1.3 ng/ml). Thus an increase in BGP concentration can be considered as a biological marker of recovered osteoblast activity during therapeutically induced stabilization or regression of skeletal metastatic lesions.

ISSN:0735-7907    

DOI:10.3109/07357908909017529

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractThe growth inhibitory effects of the fluoropyrimidines 5-flourouracil (5-FU) and 5-fluoro-2′-deoxyuridine (FdUrd) against a human squamous cell carcinoma cell line (SQ-1) were studied in the absence and presence of deoxynucleosides and/or N5-formyl-tetrahydrofolate (leucovorin). Inhibition of cell growth by the fluoropyrimidines was less when undialyzed rather than dialyzed fetal bovine serum was used. Leucovorin, in concentrations of 10--6to 10--4M potentiated the growth inhibition of FU and FdUrd; deoxyguanosine and deoxyinosine in concentrations of 10-5M also enhanced the growth inhibition produced by these fluoropyrimidines. In the presence of leucovorin addition, deoxyguanosine (10--5M) caused a further synergistic inhibition of cell growth produced by FdUrd but not FU. In contrast, addition of deoxyinosine at 10--5M resulted in further potentiation of FU but not FdUrd inhibition of cell growth in the presence of leucovorin. The synergy obtained with these combinations encourage the exploration of modulation of fluoropyrimidine by leucovorin and deoxynucleosides in vivo.

ISSN:0735-7907    

DOI:10.3109/07357908909017530

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractEighteen evaluable patients with previously untreated Stage III and IV ovarian carcinoma were treated with six cycles of intraperitoneal cisplatin with intravenous Cyclophosphamide and doxorubicin. Significant chemotherapy-related toxicities were observed, including one patient with fatal neutropenia and sepsis, two patients with transient severe nephrotoxicity, one patient with severe autonomic and motor neuropathy, and one patient with generalized debility. One patient had Tenckhoff catheter-related peritonitis, but no other morbidity was associated with the peritoneal catheters. Three of eight patients with optimal tumor bulk and none of 10 patients with suboptimal tumor bulk achieved pathologic complete response. The overall estimated median survival is 22 months. This treatment approach is associated with formidable toxicity, and the contribution of intraperitoneal cisplatin to the treatment of newly diagnosed ovarian carcinoma patients must be evaluated in randomized trials.

ISSN:0735-7907    

DOI:10.3109/07357908909017531

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909017532

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909017533

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909017534

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909017535

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909017536

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909017537

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor